TACE联合微波消融治疗BCLC B期及C期肝癌的真实世界研究

Study of TACE combined with microwave ablation therapy in treating patients with barcelona clinic liver cancer stage B and C hepatocellular carcinoma

目的 通过回顾性分析观察肝动脉灌注化疗栓塞术(TACE)联合微波消融治疗是否能使BCLC B期及C期肝癌患者获益。方法 收集2013年6月—2017年12月在吉林省肿瘤医院诊断并治疗的BCLC B期及C期原发性肝癌患者的临床资料,共107例,其中TACE+MWA联合治疗组50例,单纯TACE组57例,比较两组患者的生存情况,并对预后影响因素进行Cox回归分析。结果 在BCLC B期患者中,接受单纯TACE治疗的1、2、3年的总生存率为74.19%,41.94%,16.13%,中位OS为15个月;而采用TACE+MWA联合治疗的1、2、3年的总生存率为97.44%,66.67%,38.46%,中位OS为27个月(P=0.008),具有统计学意义,TACE+MWA可降低47%的死亡风险。结论 TACE联合MWA可使手术不可切除的BCLC B期肝癌患者获益。

ObjectiveThrough retrospective analysis to observe whether transcatheter arterial chemoembolization(TACE)combined with microwave ablation therapy can benefit patients with BCLC stage B and C hepatocellular carcinoma.MethodsCollect clinical data of patients with BCLC stage B and C hepatocellular carcinoma diagnosed and treated in Jilin Provincial Tumor Hospital from June 2013 to December 2017.A total of 107 cases were divided into two groups:50 cases in the TACE+MWA combined treatment group and 57 cases in the TACE alone group.Compare the survival conditions of the two groups of patients,and perform Cox regression analysis on prognostic factors.ResultsIn BCLC stage B patients,the 1-,2-and 3-year overall survival rates of those who received TACE alone were 74.19%,41.94%,and 16.13%,and the median OS was 15 months.The 1-,2-and 3-year overall survival rates of those with TACE+MWA combination therapy were 97.44%,66.67%,38.46%,and the median OS was 27 months(P=0.008),which was statistically significant.TACE+MWA can reduce 47%risk of death.ConclusionTACE combined with MWA can benefit patients with unresectable BCLC stag B hepatocellular carcinoma.